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Introduction
Anticoagulant therapy (AT) is the cornerstone in the treat-
ment of venous thromboembolism (VTE). Extended AT
effectively prevents recurrent events, but at the cost of
bleeding complications.1–3 The reported annual risk of
major bleeding (MB) varies in the range of 1 to 4%4–6 and
is dependent on the choice of anticoagulant, intensity of
anticoagulation, and duration of treatment.6–8 The MB risk
is particularly high within the first months of AT,2 with a









Abstract Identification of patients at risk of major bleeding is pivotal for optimal management of
anticoagulant therapy in venous thromboembolism (VTE). Studies have suggested that
D-dimer may predict major bleeding during anticoagulation; however, this is scarcely
investigated in VTE patients. We aimed to investigate the role of D-dimer, measured at
VTE diagnosis, as a predictive biomarker of major bleeding. The study population
comprised 555 patients with a first community-acquired VTE (1994–2016), who were
identified among participants from the Tromsø study. Major bleeding events were
recorded during the first year after VTE and defined according to the criteria of the
International Society on Thrombosis and Haemostasis. Cox-regression was used to
calculate hazard ratios (HRs) with 95% confidence intervals (CIs) adjusted for age, sex,
and duration of anticoagulant therapy. In total, 29 patients experiencedmajor bleeding
(incidence rate: 5.7/100 person-years, 95% CI: 4.0–8.2). The major bleeding risk was
highest during the first 3 months, especially in patients with D-dimer 8.3 µg/mL
(upper 20th percentile), with 28.8 major bleedings/100 person-years (95% CI: 13.7–
60.4). Patients with D-dimer 8.3 µg/mL had a 2.6-fold (95% CI: 1.1–6.6) higher risk of
major bleeding than patients with D-dimer 2.3 µg/mL (lower 40th percentile). Major
bleeding risk according to D-dimer 8.3 versus 2.3 µg/mL was particularly pro-
nounced among those with deep vein thrombosis (HR: 4.6, 95% CI: 1.3–16.2) and
provoked events (HR: 4.2, 95% CI: 1.0–16.8). In conclusion, our results suggest that D-
dimer measured at diagnosis may serve as a predictive biomarker of major bleeding
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Even though initially promising in derivation studies,10–12
prediction models developed to stratify risk of MB in VTE
patients have demonstrated inconsistent discriminative
powers in validation studies.13–16 The existing prediction
models mainly apply the same traditional predictors for
bleeding such as age, history of bleeding, previous stroke,
and cancer.10–12 Identification of novel predictors for bleed-
ing in VTE patients is therefore an essential step for the
development of a more accurate prediction score for MB,
capable of guiding clinical decision-making in the future.
D-dimer, a global biomarkerof activationof the coagulation
andfibrinolytic systems, isuseful toexcludeaVTE-diagnosis in
the diagnostic work-up of suspected acute VTE.17 Moreover,
elevated D-dimer is used to identify patients at high risk of
VTE-recurrence after discontinuation of AT.18,19 Interestingly,
elevated D-dimer levels have also been shown in conditions
associated with increased bleeding risk, such as disseminated
intravascular coagulation and acute abdominal aortic dissec-
tion.20,21 Furthermore, high D-dimer levels appeared to pre-
dict MB during AT.22 However, studies on VTE patients are
scarce,23 andwhetherD-dimermeasured at VTEdiagnosis can
beused to assess riskofMB is largely unknown. Informationon
D-dimerat thetimeofVTEdiagnosis is easilyavailable formost
patients with community-acquired VTE, as D-dimer is fre-
quently used for the diagnosticwork-up ofVTE.24Weaimed to
investigate the roleofD-dimer,measuredatVTEdiagnosis, asa




The source population comprised subjects participating in
1 of the six currently completed surveys of the Tromsø
study (Tromsø 1–6), who were still alive and inhabitants of
Tromsø by January 1, 1994 (n ¼ 33,885). The Tromsø study is
a single-center, population-based prospective cohort, with
repeated health surveys of the inhabitants of Tromsø, Nor-
way.25 Overall, participation rates were high, ranging from
85% in Tromsø 2 to 66% in Tromsø 6, with an average of 78.5%
for the six surveys. The study was approved by the Regional
Committee of Medical and Health Research Ethics, and all
participants gave their informed written consent.
All potential first lifetime VTE cases were identified from
January 1, 1994 to December 31, 2016 by searching the
hospital discharge diagnosis registry, the autopsy registry,
and the radiology procedure registry at the University Hos-
pital of North Norway (UNN). The UNN is the only hospital
serving the source population and all outpatient care for
diagnostic assessment and treatment of VTE is exclusively
provided at this hospital. The medical records of each poten-
tial VTE case were reviewed by trained personnel, and a VTE
event was confirmed and registered as a validated VTEwhen
clinical signs and symptoms of proximal or distal deep vein
thrombosis (DVT) or pulmonary embolism (PE) were com-
bined with objective confirmation by diagnostic procedures,
and resulted in a VTE diagnosis requiring treatment, as
described in detail previously.26 Using the aforementioned
strategy, a total of 986 objectively confirmed VTE cases were
identified. D-dimer has low specificity for the diagnosis of
VTE as it is often elevated in patients hospitalized for other
conditions or with cancer.27–29 We therefore excluded sub-
jects with active cancer (n ¼ 230) and those already hospi-
talized for other conditions (n ¼ 108) when the VTE
occurred. Moreover, subjects with high clinical suspicion
leading to a VTE diagnosis without the aid of D-dimer
measurement were also excluded (n ¼ 93), leaving 555
VTE patients eligible for this study. These patients were
followed for 365 days, and all bleeding events occurring in
this period were recorded by thorough review of medical
records.
Clinical Characteristics
Information on clinical and provoking factors at the time of
and 12 weeks preceding the VTE diagnosis was obtained for
all eligible patients. Patients with provoked VTE were those
with major surgery, trauma, or an acute medical condition
(acute myocardial infarction, ischemic stroke, or major
infectious disease) within 12 weeks prior to VTE event,
marked immobilization (confined to bed >3 days, wheel-
chair, or long-distance travel exceeding 4 hours within the
last 14 days prior to VTE event), or any other factor speci-
fically described in themedical records to have provoked the
VTE (e.g., intravascular catheter).
Even though the study population was originated from a
prospective cohort study (the Tromsø study), data collection
for the present study was conducted retrospectively. To
account for treatment duration in the present study, we
considered the planned duration of anticoagulation that was
objectively described by the attending physicians in the
medical records at the time of VTE diagnosis. Duration of
ATwas categorized into 3, 6, and 12 months according to the
preplanned length of AT. When the treatment duration was
not specified by the treating physician (n ¼ 42), subjects
were categorized into 3 months if the incident event was a
provoked DVT, 6 months if it was an unprovoked DVT, and
12 months if it was a PE.
Outcome Assessment of Major Bleeding
For each study participant, MB events occurring during the
365 days following the VTE were identified by thorough
reviewof themedical records at the UNN. This hospital is the
exclusive provider of advanced health care, including trans-
fusion of blood products and emergency medicine in a
vicinity of 250 km, and all subjects with a significant bleed-
ing event in the Tromsø region are likely to be admitted at
this hospital. Two reviewers (trainedmedical personnel from
the UNN) adjudicated the bleeding events independently in
accordance with the criteria proposed by the International
Society on Thrombosis and Haemostasis.30 In short, a bleed-
ing event that was fatal, and/or symptomatic in a critical area
or organ, and/or requiring blood transfusion of 2 units of
red blood cells or causing a fall in hemoglobin level of20 g/L
was consideredmajor. In case of disagreement, the event was
discussed in an endpoint committee (H.S.J. and J.B.H.) to
reach consensus.
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D-Dimer Measurement
Blood samples were drawn for the diagnostic work-up of
VTE, before initiation of AT. D-dimer was determined using
two commercially available kits at theDepartment of Clinical
Chemistry at the UNN,31 and a D-dimer value <0.5 μg/mL
was defined as a negative test in the diagnostic work-up of
patients with suspected VTE. The NycoCard D-dimer assay
(Nycomed Pharma, Oslo, Norway), based on immunometric
flow-through principle, was used in the period 1994 to 1998.
It was succeeded by the STA-Liatest D-Di assay (Diagnostica
Stago, Asnières-sur-Seine, France) for the remaining period
(1998–2016). The Stago assay quantified D-dimer by the
immuno-turbidimetric method (liquid reagent) within a
range of 0.27 to 20 µg/mL, which determined the levels of
D-dimer available in this study.
Statistics
Subjects were followed from the date of their first VTE to the
date of an incidentMB, death, migration from Tromsø, or end
of follow-up (i.e., 365 days after the first VTE), whichever
came first. The patients were followed for 1 year, regardless
of the length of anticoagulation. Thus, the follow-up time
included both time-on and time-off anticoagulant treat-
ment. Subjects who died or migrated were censored at the
time of the respective event. Statistical analyses were per-
formed with STATA version 15.0 MP (Stata Corp. College
Station, Texas, United States).
D-dimer levels were initially divided into quintiles. The
two lowest (Q1–2) and the two middle-upper (Q3–4) quin-
tiles were combined to achieve better statistical power (i.e., a
more robust reference category), and to enable the assess-
ment ofMB risk according to the highest D-dimer levels (Q5).
The two lowest quintiles (Q1–2) were set as the reference.
Crude incidence rates (IRs) with 95% confidence intervals
(CIs) of MB were calculated across D-dimer categories and
expressed as number of events per 100 person-years at risk.
Cox proportional hazards regression models were used to
estimate hazard ratios (HRs) with 95% CIs for MB. The HRs
were estimated using the following models: the first model
was adjusted for age and sex, and the secondwas additionally
adjusted for the planned duration of AT. Since a large severe
thrombus could result in both high D-dimer levels and
prolonged treatment, the treatment length was added as a
potential confounder in the second model. The proportional
hazards assumption was verified by evaluating the paralle-
lism in the log–log survivor function by the categorical
division of D-dimer. Further, the association between D-
dimer levels andMB, adjusted for age, sex, and duration of AT,
was visualized by a generalized additive regression plot
using R version 3.4.4, to assess potential nonlinear effects
of D-dimer levels on MB risk. D-dimer was modeled with a
smoothing spline fit in a Cox proportional hazards model.
Due to potentially higher all-cause mortality rates in the
upper D-dimer category, we additionally performed compet-
ing risk by death analyses and calculated subdistribution
hazard ratios (SHRs) to limit overestimation of the relative
risk differences of MB between D-dimer categories.32,33 The
1-year cumulative incidences of MB across D-dimer cate-
gories were visualized in traditional one minus Kaplan–
Meier (1-KM) plots and in cumulative incidence function
plots corrected for competing risk by death.
We performed subgroup analyses stratified by clinical
presentation (i.e., DVT and PE with or without DVT) and
presence of provoking risk factors at the time of VTE diagnosis
(i.e., unprovoked and provoked events). For overall VTE, we
also assessed the risk of MB in analyses restricted to the first
3 months after VTE diagnosis (i.e., the period in which all
patientswould be on anticoagulant treatment). For sensitivity
purposes, we performed analyseswherewe excluded patients
who received thrombolytic therapy (systemic or catheter-
directed) for VTE treatment, as these patients might be at
increased bleeding risk.3 We also did sensitivity analyses
where patients were censored at the time they stopped antic-
oagulant treatment (estimated according to the planned dura-
tionofanticoagulation), toassess the riskofbleedingaccording
to D-dimer restricted to the time on anticoagulant treatment.
Results
Baseline characteristics according to D-dimer categories are
shown in►Table 1. D-dimer levels were in the ranges of2.3,
2.4 to 8.2, and8.3 µg/mL in the lowest (Q1–2),middle (Q3–4),
Table 1 Baseline characteristics of venous thromboembolism







Range (µg/mL) 2.3 2.4–8.2 8.3
Age (y), mean  SD 64  15 67  14 69  14
Sex (males) 44.0 (99) 56.2 (123) 50.5 (56)
Previous stroke 3.6 (8) 5.5 (12) 10.8 (12)
Thrombolytic therapy 1.8 (4) 6.9 (15) 10.8 (12)
Planned duration of anticoagulation
 3 mo 24.9 (56) 16.9 (37) 9.9 (11)
> 3 including 6 mo 43.6 (98) 48.0 (105) 38.7 (43)
> 6 including 12 mo 24.4 (55) 26.0 (57) 37.8 (42)
> 12 mo 7.1 (16) 9.1 (20) 13.5 (15)
VTE characteristics
DVT 57.8 (130) 60.7 (133) 46.0 (51)
PE  DVT 42.2 (95) 39.3 (86) 54.0 (60)
Unprovoked 64.0 (144) 59.8 (131) 60.4 (67)
Provoked 36.0 (81) 40.2 (88) 39.6 (44)
Trauma 12.0 (27) 10.0 (22) 10.8 (12)
Surgery 12.4 (28) 13.7 (30) 12.6 (14)
Acute medical
condition
4.4 (10) 7.8 (17) 13.5 (15)
Confined to
bed >3 days
1.8 (4) 1.8 (4) 2.7 (3)
Abbreviations: DVT, deep vein thrombosis; mo, months; PE, pulmonary
embolism; SD, standard deviation.
Note: Categorical variables are shown as percentages with numbers in
brackets, % (n).
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and upper (Q5) categories, respectively. The mean age and
proportion of subjects with acute medical conditions preced-
ing the VTE were higher in the upper than in the lower
categories of D-dimer. Moreover, a higher proportion received
thrombolytic therapy, and the planned duration of AT was
longer in the highest category of D-dimer. The proportion of
patients with PE was higher in the upper category, whereas
DVTsweremore frequent in the two lowest categories.Of note,
missing information on duration of AT was similarly distrib-
uted across the lowest (7.6%), middle (7.3%), and upper (8.1%)
D-dimer categories. The baseline characteristics of the overall
study population can be found in►Supplementary Table S1 .
Of the 555 patients with incident VTE, 29 had a MB event
within 1 year after the incident VTE, yielding an overall IR of
5.7 per 100 person-years (95% CI: 4.0–8.2). The median and
mean times from VTE diagnosis to MBwere 35 and 113 days,
respectively.MBs that were intramuscular with symptoms of
compartment syndrome and gastrointestinal bleedingswere
most frequent (27.6%), followed by intracranial MBs (17.2%)
(►Table 2).
The 1-year cumulative incidences of MB across categories
of D-dimer were estimated by 1-KM (►Fig. 1A), and in the
presence of death as competing risk (►Fig. 1B), as displayed
in►Fig. 1. The cumulative incidence of MB was considerably
higher for the upper D-dimer category than for the lower and
middle D-dimer categories (►Fig. 1A). The results remained
essentially similar after taking competing risk by death into
account (►Fig. 1B). Themajorityof theMB events occurred in
thefirst 3months after the VTE, and the 3-month cumulative
incidences of MBwere 2.2%, 2.5%, and 6.8% for patients in the
lower, middle, and upper categories of D-dimer, respectively
(►Fig. 1B). At 12 months the cumulative incidences for the
lower, middle, and upper categories were 3.6%, 4.1%, and
10.8%, respectively (►Fig. 1B).
The 3-month and 12-month IRs and HRs of MB in the
overall population according to D-dimer categories are pre-
sented in►Table 3. At 12months, the crude IR ofMBwas 13.1
per 100 person-years (95% CI: 7.5–23.1) in the upper cate-
gory of D-dimer, versus 4.6 (95% CI: 2.4–8.9) and 3.8 (95% CI:
1.9–7.5) per 100 person-years in the middle and lower
categories, respectively. In the model adjusted for age, sex,
and duration of AT, patients with a D-dimer in the upper
category (8.3 µg/mL) had a 2.6-fold higher risk of MB (HR:
2.6, 95% CI: 1.1–6.6) compared with those with a D-dimer in
the lowest category (2.3 µg/mL). When analyses were
restricted to thefirst 3months of follow-up, the crude overall
IR of MB was 13.9 per 100 person-years (95% CI: 8.8–22.1),
and likewise the risk increased across categories of D-dimer,
with an IR in the upper category of 28.8 per 100 person-years
(95% CI: 13.7–60.4). Exclusion of patients who received
thrombolytic therapy (n ¼ 31) yielded similar results as
the main analyses (►Supplementary Table S2). The general-
ized additive regression plot revealed that the risk of MB
started to increase at D-dimer levels >7.0 µg/mL (►Fig. 2).
Stratification according to specific subgroups (provoked,
unprovoked, DVT, and PE) revealed that the association
between D-dimer and MB was particularly pronounced
among patients with DVTs and provoked events. In age-,
sex-, and duration of AT-adjusted models, the HRs of MB
according to D-dimer 8.3 versus 2.3 µg/mL were 4.6 (95%
CI: 1.3–16.2) for patients with DVT and 4.2 (95% CI: 1.0–16.8)
for those with provoked VTE (►Table 4). In contrast, a D-
dimer 8.3 µg/mL was associated with a marginally
increased risk of MB in patients with PE (HR: 1.7, 95% CI:
Table 2 Sites of major bleeding (MB) in patients with venous
thromboembolism
Bleeding site MB, % (n)





aOther sites of MB included pericardial, retroperitoneal, and subcutaneous
(hematoma).
Fig. 1 One year cumulative incidence of major bleeding by categories of D-dimer estimated by 1-Kaplan–Meier (A) and in the presence of death
as competing event (B).
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0.4–6.9) or unprovoked events (HR: 1.5, 95% CI: 0.4–5.9), but
the results were not statistically significant. As in the overall
analyses (►Table 3), the results were only slightly attenuated
in the competing risk model (►Table 4), as demonstrated by
the SHRs.
Among the 29 MB events, only one case occurred after the
preplanned treatment length. Sensitivity analyses restricted to
the timeonanticoagulant treatment showedessentially similar
results (►Supplementary Table S3 and ►Supplementary
Fig. S1).
Discussion
In this population-based cohort study of patients with a first
lifetime community-acquired VTE, we found that patients
with high D-dimer levels (8.3 µg/mL) had 2.6-fold higher
risk of a MB during the 1 year of follow-up compared with
those with D-dimer levels 2.3 µg/mL. The risk of MB was
highest during the first fewmonths after the VTE. In patients
with high D-dimer, the 3-month cumulative incidence of MB
was 6.8%, whereas the cumulative incidence for the entire
12-month follow-up was 10.8%. The risk of MB among
patients with D-dimer 8.3 µg/mL was especially high for
those with DVTs and provoked events. Our findings suggest
that a highD-dimer value at VTE diagnosis identifies patients
at increased risk of MB events, particularly in the initial
phase of anticoagulant treatment.
In the present study, the overall 1-year IR of MB was 5.7
per 100 person-years, which is comparable to previously
reported rates of MB in patients treated with warfarin.34
Consistent with previous data,2 we found that the IR of MB
was notably high during the first 3 months after VTE,
especially in those with high D-dimer (28.8 MBs per 100
person-years). Possible explanations for the initially high
bleeding risk may include overanticoagulation due to the
wide intra- and interindividual variability in the dose-
requirements in patients treated with vitamin K antagonists
(VKAs),35,36 and the initial administration of concomitant
lowmolecular weight heparin. Furthermore, patients with a
bleeding predisposition are more likely to experience a MB
early after initiation of AT.3
Our results are consistent with previous studies on atrial
fibrillation,37,38 such as the ARISTOTLE-trial,37 where
patientswith a D-dimer1,123 µg/L had a twofold increased
risk of MB compared with those with a D-dimer <423 µg/L.
To date, only a few studies, with substantial differences in
designs and sample sizes, have examined the association of
D-dimer with risk of MB in VTE patients.22,23 In line with our
results, a study of 1,707 PE patients from the RIETE-registry
found that a D-dimer 4.2 µg/mL was associated with
increased risk of MB within 15 days of PE diagnosis.23 In a
study comprising 719 patients treated with VKA for at least
2 months before inclusion, of whom only 11% had VTE, Lind
et al found that high D-dimer levels, measured during AT,
were associated with increased risk of MB.22 To the best of
our knowledge, the present study is the first to provide data
on the association between D-dimer and risk of MB in a
cohort of community-acquired VTE, encompassing both DVT
and PE, without active cancer at the time of VTE diagnosis.
Table 3 Incidence rates (IRs) and risk of major bleeding (MB) by categories of D-dimer at 12 and 3 months of follow-up after
incident venous thromboembolism
12 mo (D-dimer, µg/mL) MB IR (95% CI)a HR (95% CI)b HR (95% CI)c SHR (95% CI)c
Q1–2 2.3 8 3.8 (1.9–7.5) Ref. Ref. Ref.
Q3–4 2.4–8.2 9 4.6 (2.4–8.9) 1.1 (0.4–2.9) 1.1 (0.4–2.8) 1.0 (0.4–2.6)
Q5 8.3 12 13.1 (7.5–23.1) 2.9 (1.1–7.1) 2.6 (1.1–6.6) 2.5 (1.0–6.3)
3 mo
Q1–2 2.3 5 9.3 (3.9–22.4) Ref. Ref. Ref.
Q3–4 2.4–8.2 6 11.7 (5.3–26.1) 1.2 (0.4–3.9) 1.2 (0.4–3.9) 1.2 (0.4–3.8)
Q5 8.3 7 28.8 (13.7–60.4) 2.6 (0.8–8.4) 2.6 (0.8–8.6) 2.5 (0.7–8.8)
Abbreviations: CI, confidence interval; HR, hazard ratio; mo, months; SHR, subdistribution hazard ratio.
aPer 100 person-years.
bAdjusted for age and sex.
cAdjusted for age, sex, and planned duration of anticoagulation. SHR denotes the HR after taking competing risk by death into account.
Fig. 2 The risk of major bleeding (MB) as a function of D-dimer
adjusted for age, sex, and planned treatment duration in a generalized
additive regression model. The solid line shows hazard ratios (HRs),
enclosed by shaded area showing 95% confidence intervals. The
distribution of D-dimer is shown as density plots at the bottom, and in
quintiles at the vertical lines.
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In our study, the risk of MB in patients with high D-dimer
levels was most pronounced among those with provoked
events. It is reasonable to assume an overestimation of the
MB risk for comorbidities with high mortality rates.33,39,40
However, the risk estimates for MB remained essentially
similar when the competing risk of death was taken into
account. Hence, our findings suggest that the association
between high D-dimer and MB risk in subjects with provoked
VTE could not be explained by an overestimation due to high
mortality rates. Still, other medical conditions associatedwith
increased riskofprovokedDVT,butnotnecessarilywithhigher
mortality within the first year after an incident VTE, could be
relevant for the association between D-dimer and MB.29,41
Several studies have shown that elevated D-dimer is asso-
ciated with increased risk of recurrence in patients with
unprovoked VTE.18,19 Using data from the Tromsø study, we
recently reported that a low D-dimer (1.5 µg/mL), measured
at first VTE diagnosis, was associated with a low recurrence
risk, particularly among patients with DVTs and unprovoked
events.31 In the present study, we found that a high D-dimer,
also measured at VTE diagnosis, was associated with risk of
MB. Intuitively, for the purpose ofdiscriminating betweenVTE
patients at high risk of either MB or recurrent VTE, such a
predictive factor may appear noninformative, as D-dimer is
associated in the same direction for both outcomes. However,
the risk of MB and recurrence seemed to be most pronounced
in different parts of the spectrum of D-dimer values. Only the
very high levels of D-dimer (>7.0 µg/mL) were predictive of
MB, whereas the recurrence risk did not further increase for
D-dimer levels>1.5 µg/mL (threshold effect).31Moreover, the
risk of MB and recurrence displayed different patterns in
cumulative incidence curves. For recurrence, the risk gradually
increased over years in patientswith a D-dimer1.5 µg/mL,31
whereas for MB, the risk rapidly increased within the first
3 months after the incident VTE in patients with a D-dimer
8.3 µg/mL.
Our findings have potential clinical implications for the
management of VTE during anticoagulation. D-dimer may be
used as a predictive biomarker for MB to guide decisions on
duration of AT, particularly in combination with clinical pre-
dictors ofMB.13 Importantly, thismay be achievedwithout the
need for additional blood sampling or cost as D-dimer is
measured at VTE diagnosis in most patients. Given that the
absolute risk and potential to preventMB is highest during the
first fewmonths of anticoagulation, D-dimermayhave clinical
utility for the short-term management of VTE. Improved
assessment of individual bleeding risk may impact clinical
management, such as the choice of anticoagulant drug, careful
supervision of anticoagulation, prompt investigation of minor
gastrointestinal or urogenital bleeding to eliminate possible
sources of future MB, or avoidance of concomitant therapies
that may cause bleeding (e.g., antiplatelet agents and nonster-
oidal anti-inflammatory drugs).42 Moreover, after a first
unprovoked event, identification of patients at high risk of
bleeding is of utmost importance for decisions on extended
duration of AT.43 Even though we found relatively weak
associations betweenD-dimer levels and riskofMB inpatients
with unprovoked events, the potential of D-dimer as a con-
tributing building block in a prediction model in this specific
patient group remains to be determined. Finally, during the
study period, the majority of the patients in our study were
treated with VKAs, as direct oral anticoagulants (DOACs)
Table 4 Incidence rates (IRs) and risk of major bleeding (MB) by categories of D-dimer in subgroups of venous thromboembolism
DVT (n ¼ 314) (D-dimer, µg/mL) MB IR (95% CI)a HR (95% CI)b HR (95% CI)c SHR (95% CI)c
Q1–2 2.3 4 3.2 (1.2–8.5) Ref. Ref. Ref.
Q3–4 2.4–8.2 6 4.9 (2.2–10.9) 1.5 (0.4–5.3) 1.1 (0.3–4.1) 1.1 (0.3–3.9)
Q5 8.3 8 19.9 (10.0–39.8) 5.0 (1.4–17.7) 4.6 (1.3–16.2) 4.4 (1.1–18.1)
PE (n ¼ 241)
Q1–2 2.3 4 4.5 (1.7–11.9) Ref. Ref. Ref.
Q3–4 2.4–8.2 3 3.8 (1.2–11.8) 0.8 (0.2–3.6) 0.8 (0.2–3.6) 0.8 (0.2–3.3)
Q5 8.3 4 7.5 (2.8–20.0) 1.7 (0.4–6.8) 1.7 (0.4–6.9) 1.5 (0.3–7.8)
Unprovoked (n ¼ 342)
Q1–2 2.3 5 3.6 (1.5–8.7) Ref. Ref. Ref.
Q3–4 2.4–8.2 5 4.1 (1.7–9.9) 1.1 (0.3–3.9) 1.1 (0.3–3.9) 1.1 (0.3–3.7)
Q5 8.3 4 6.7 (2.5–17.8) 1.7 (0.5–6.5) 1.5 (0.4–5.9) 1.5 (0.3–6.1)
Provoked (n ¼ 213)
Q1–2 2.3 3 3.9 (1.3–12.2) Ref. Ref. Ref.
Q3–4 2.4–8.7 4 5.0 (1.9–13.2) 1.0 (0.2–4.5) 0.8 (0.2–3.7) 0.8 (0.2–3.5)
Q5 8.8 8 23.9 (12.0–47.8) 4.2 (1.0–16.9) 4.2 (1.0–16.8) 3.6 (0.9–14.8)
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; HR, hazard ratio; PE, pulmonary embolism; SHR, subdistribution hazard ratio.
aPer 100 person-years.
bAdjusted for age and sex.
cAdjusted for age, sex, and planned duration of anticoagulation. SHR denotes the HR after taking competing risk by death into account.
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became available for clinical practice in Norway around 2012.
Therefore, future studies are needed to confirm ifD-dimer also
is a predictive biomarker of bleeding in patients treated with
DOACs.
The inclusion of subjects derived from the general popu-
lation is among the main strengths of the present study. In
contrast, bleeding complications are often studied as a safety
outcome in randomized clinical trials, which tend to include
selected patients compared with those from population-
based studies, whose clinical characteristics more likely
reflect real-life patients. Other strengths include the pro-
spective design, complete and validated registry of VTE
events, and the exclusivity of UNN as the sole health care
provider, likely to receive all relevant MB events. The study
also has some limitations. Our results are not generalizable to
patients already hospitalized for other conditions or with
active cancer when the VTE occurred. For this patient group,
however, D-dimer may already be of limited clinical utility
given its reduced specificity in the diagnostic work-up of
VTE.27,28 Even though the UNN is the sole health care
provider within a geographically well-defined region, we
cannot rule out the unlikely possibility that a MB event was
not captured due to the retrospective collection of data. In
this study, we did not have access to information on the
actual duration of anticoagulant treatment, and we based
our adjustments on the preplanned treatment length. This
could have led to misclassification of treatment length in
some patients. Nevertheless, when we restricted our ana-
lyses to the first 3months after VTE diagnosis (i.e., the period
in which all patients would be on anticoagulant treatment),
the results were essentially similar to the overall analyses,
showing an increased risk of MB associated with a high D-
dimer value (8.3 µg/mL). Unfortunately, we did not have
information on the concomitant use of drugs that might
affect the bleeding risk, such as the use of antiplatelet
medication. Approximately 14% of eligible patients were
excluded because of missing D-dimer values. Of these, there
were three MB events, yielding an IR of 3.5 per 100 person-
years (95% CI: 1.1–10.9), whichwas lower comparedwith the
rate of the included population. However, this ratewas based
on few MBs, and clinical characteristics were not widely
different in those with measured and missing D-dimer (data
not shown). Taken together, missing values of D-dimer was
presumably at random, and would unlikely introduce selec-
tion bias. We used two different assays to measure D-dimer
levels, which might have led to misclassification due to
varying analytical properties across D-dimer assays.44 How-
ever, the STA-Liatest, which has consistently reported excel-
lent analytical properties,45,46 was used for 93.5% of the
study population, thus limiting misclassification. Moreover,
in sensitivity analysis restricted to subjects with D-dimer
determined by the STA-Liatest, the results remained essen-
tially the same (data not shown). Finally, our results should
be interpretedwith caution due to lownumbers ofMB events
and limited statistical power, mainly in subgroup analyses.
In conclusion, our findings suggest that high levels of D-
dimer ( 8.3 µg/mL), measured at the time of first VTE
diagnosis, identify patients at increased risk of MB, particu-
larly during the first 3 months of AT. Future studies are
warranted to confirm our findings and to investigate
whether D-dimer at VTE diagnosis could improve risk stra-
tification of MB when added to existing prediction models.
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